Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007)

Clinical trial NCT04317040 · COMPLETED

Trial details

NCT number

NCT04317040

Sponsor

Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Status

COMPLETED

Phase

Phase 3

Study type

INTERVENTIONAL

Start date

2020-04-24

Primary completion

2020-10-20

Enrollment

234

View on ClinicalTrials.gov